Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.53 and traded as low as $3.42. Cryo-Cell International shares last traded at $3.45, with a volume of 2,075 shares.

Cryo-Cell International Trading Up 1.8%

The firm’s fifty day moving average price is $3.52 and its 200 day moving average price is $3.53. The firm has a market capitalization of $27.81 million, a PE ratio of -10.45 and a beta of 0.48.

Cryo-Cell International (NYSEAMERICAN:CCEL) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $7.68 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International as of its most recent SEC filing. 10.44% of the stock is owned by hedge funds and other institutional investors.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.